Pneumologie最新文献_第6页

Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells. 地塞米松、雷米地韦和阿奇霉素调节肺上皮细胞中的 ACE2 和 IL-6

IF 1.2

Pneumologie Pub Date : 2025-02-01 Epub Date: 2024-09-16 DOI: 10.1055/a-2372-3632

Gudrun Sigrid Ulrich-Merzenich, Anastasiia Shcherbakova, Carmen Pizarro, Dirk Skowasch

{"title":"Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells.","authors":"Gudrun Sigrid Ulrich-Merzenich, Anastasiia Shcherbakova, Carmen Pizarro, Dirk Skowasch","doi":"10.1055/a-2372-3632","DOIUrl":"10.1055/a-2372-3632","url":null,"abstract":"Background: The optimal use of steroids in COVID-19 patients remains challenging. Current S3-guidelines \"Recommendations for patients with COVID-19\" recommend dexamethasone (DEX) for patients requiring respiratory support, remdesivir (RD) in the early disease phase and azythromycin (AZ) is no longer recommended. We investigated effects of DEX, RD and AZ in a lipopolysaccharide induced inflammation in lung cells in vitro and analyzed publicly available datasets with a focus on the Angiotensin-converting enzyme 2 (ACE2) to better understand drugs' mechanisms of action.Methods: human bronchial (Calu) and alveolar (A549) lung epithelial cells were treated with DEX, AZ or RDV in the presence of lipopolysaccharides (LPS). Gene expression (GE) of ACE2, IL-6 and the IL-6 protein release were measured. Publicly available GE data from lung tissues of COVID-19 patients and from lung cells treated with DEX were analyzed for the GE of ACE2.Results: DEX increased and RDV and AZ reduced the GE of ACE2 in LPS-stimulated bronchial and alveolar epithelial cells. Only DEX significantly reduced LPS-induced IL-6 releases in alveolar cells substantially. The database analyses showed an, albeit not always significant, increase in ACE2 for lung tissue or cell lines treated with DEX. Lung tissue from patients after COVID-19 infection as well as bronchial cell cultures after COVID-19 infection showed lower GEs of ACE2.Discussion and conclusion: DEX can increase ACE2 expression in vitro and thereby the portal of entry of SARS-CoV-2 into lung cells during an LPS induced inflammation. Simultaneously the inflammatory marker IL-6 is reduced. Comparative database analyses indicate that these processes can also take place in vivo.","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"134-140"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Recommendations for training courses in bronchoscopy - update 2024]. [支气管镜检查培训课程建议- 2024年更新]。

IF 1.2

Pneumologie Pub Date : 2025-02-01 Epub Date: 2024-12-05 DOI: 10.1055/a-2493-5802

Lars Hagmeyer, Ralf-Harto Hübner, Kaid Darwiche, Ralf Eberhardt, Andreas Gebhardt, Felix Herth, Angelique Holland, Joanna Krist, Carmen Pizarro, Gregor Zimmermann, Manfred Wagner

引用次数: 0

[Interest-driven framing: the language of the nicotine industry]. [利益驱动的框架：尼古丁行业的语言]。

IF 1.2

Pneumologie Pub Date : 2025-01-23 DOI: 10.1055/a-2508-1456

Waltraud Posch, Sabina Ulbricht, Reiner Hanewinkel

{"title":"[Interest-driven framing: the language of the nicotine industry].","authors":"Waltraud Posch, Sabina Ulbricht, Reiner Hanewinkel","doi":"10.1055/a-2508-1456","DOIUrl":"https://doi.org/10.1055/a-2508-1456","url":null,"abstract":"The consumption of conventional tobacco products has been declining for years. As a result, the tobacco and nicotine industry has opened up new markets and now has a range of different nicotine products in its portfolio. The aim of the present study was to show how the nicotine industry uses language to create awareness and characterize new nicotine products as supposedly less risky than traditional tobacco products.Key terms introduced by the tobacco and nicotine industry are identified as exemplifying the interest-driven linguistic framing of new nicotine products.Terms introduced by the tobacco and nicotine industry such as \"reduced-risk\", \"smoke- and tobacco-free\", \"vaping\", \"alternative products\" can be understood as a targeted marketing strategy that trivializes the risks associated with the use of e-cigarettes, tobacco heaters and other products.The tobacco and nicotine industry has managed to establish a friendly and reassuring terminology for the newly introduced nicotine products. It is a major challenge to replace these terms with a nomenclature that adequately describes the health risks, in particular the risk of addiction and health hazards of consuming these nicotine products. Appropriate proposals will be made.","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Comorbidity of Lung Cancer and ILD: A Review. 肺癌和ILD的合并症：综述。

IF 1.2

Pneumologie Pub Date : 2025-01-22 DOI: 10.1055/a-2512-8349

Mark Uhlenbruch, Markus Polke, Damian von Eiff, Aris Koryllos, Stefan Krüger

引用次数: 0

[S3 Guideline: Treating Chronic Respiratory Failure with Non-invasive Ventilation]. [S3指南：使用无创通气治疗慢性呼吸衰竭]。

IF 1.2

Pneumologie Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.1055/a-2347-6539

Sarah Bettina Stanzel, Jens Spiesshoefer, Franziska Trudzinski, Christian Cornelissen, Hans-Joachim Kabitz, Hans Fuchs, Matthias Boentert, Tim Mathes, Andrej Michalsen, Sven Hirschfeld, Michael Dreher, Wolfram Windisch, Stephan Walterspacher

{"title":"[S3 Guideline: Treating Chronic Respiratory Failure with Non-invasive Ventilation].","authors":"Sarah Bettina Stanzel, Jens Spiesshoefer, Franziska Trudzinski, Christian Cornelissen, Hans-Joachim Kabitz, Hans Fuchs, Matthias Boentert, Tim Mathes, Andrej Michalsen, Sven Hirschfeld, Michael Dreher, Wolfram Windisch, Stephan Walterspacher","doi":"10.1055/a-2347-6539","DOIUrl":"10.1055/a-2347-6539","url":null,"abstract":"The S3 guideline on non-invasive ventilation as a treatment for chronic respiratory failure was published on the website of the Association of the Scientific Medical Societies in Germany (AWMF) in July 2024. It offers comprehensive recommendations for the treatment of chronic respiratory failure in various underlying conditions, such as COPD, thoraco-restrictive diseases, obesity-hypoventilation syndrome, and neuromuscular diseases. An important innovation is the separation of the previous S2k guideline dating back to 2017, which included both invasive and non-invasive ventilation therapy. Due to increased scientific evidence and a significant rise in the number of affected patients, these distinct forms of therapy are now addressed separately in two different guidelines.The aim of the guideline is to improve the treatment of patients with chronic respiratory insufficiency using non-invasive ventilation and to make the indications and therapy recommendations accessible to all involved in the treatment process. It is based on the latest scientific evidence and replaces the previous guideline. This revised guideline provides detailed recommendations on the application of non-invasive ventilation, ventilation settings, and the subsequent follow-up of treatment.In addition to the updated evidence, important new features of this S3 guideline include new recommendations on patient care and numerous detailed treatment pathways that make the guideline more user-friendly. Furthermore, a completely revised section is dedicated to ethical issues and offers recommendations for end-of-life care. This guideline is an important tool for physicians and other healthcare professionals to optimize the care of patients with chronic respiratory failure. This version of the guideline is valid for three years, until July 2027.","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"25-79"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prolonged weaning after long-term ventilation due to SARS-CoV-2 infection: a multicenter retrospective analysis]. [SARS-CoV-2感染导致长期通气后延长断奶时间：一项多中心回顾性分析]。

IF 1.2

Pneumologie Pub Date : 2025-01-01 Epub Date: 2024-08-15 DOI: 10.1055/a-2370-1763

Florian Geismann, Lucas Braunschmidt, Arno Mohr, Thorsten Hardebusch, Michael Westhoff, Michael Dreher, Tobias Müller, Alexander Heine, Hemendra Ramdatt, Anne Obst, Ralf Ewert

{"title":"[Prolonged weaning after long-term ventilation due to SARS-CoV-2 infection: a multicenter retrospective analysis].","authors":"Florian Geismann, Lucas Braunschmidt, Arno Mohr, Thorsten Hardebusch, Michael Westhoff, Michael Dreher, Tobias Müller, Alexander Heine, Hemendra Ramdatt, Anne Obst, Ralf Ewert","doi":"10.1055/a-2370-1763","DOIUrl":"10.1055/a-2370-1763","url":null,"abstract":"Some of the patients with SARS-CoV-2 infection (COVID-19) received invasive ventilation during inpatient care. Weaning from ventilation was difficult for some patients (so-called prolonged weaning).Patients: Patients (n=751) with prolonged weaning (reason for ventilation \"pneumonia\" and \"acute respiratory failure\") from four centers for the period 2011-23 from the \"WeanNet\" registry were used as a matched group.Results: The median duration of intensive medical care was 39 (25-68) days. In 19% (37/193) of patients, ECMO support was necessary for a median of 27 (18-51) days. In-hospital mortality was 8.3% (2.7% with vs. 9.6% without ECMO) and 6.8% died in the comparison group. At discharge, 84% (vs. 77% in the control group) were completely weaned and 2.6% (vs. 17.6% in the control group) of patients received non-invasive treatment. Invasive ventilation was still necessary in 7.8% (control group 15.7%). In the observation period of 6 months after discharge, 22.4% of patients required inpatient care and a further 14.1% after 12 months. The overall mortality at 12-month follow-up was 20,6% (5.6% with vs. 24.6% without ECMO).Discussion: The mortality rate of ventilated patients with COVID-19 was very low at 8.3% in the four weaning centers studied. The mortality rate of patients with ECMO treatment was only 2.7%. The mortality rate in the control group was 7.3%. The lower mortality of patients with ECMO treatment was also evident at follow-up of up to 12 months.Patients with prolonged weaning who received invasive ventilation due to COVID-19 showed comparable results in terms of successful weaning and mortality compared to a control group from the WeanNet registry. The long-term results with a survival of more than 80% for the first year after discharge were encouraging.","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"80-86"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Neoadjuvant therapy for resectable non-small cell lung cancer]. 可切除的非小细胞肺癌的新辅助治疗。

IF 1.2

Pneumologie Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1055/a-2465-4830

Katrin Welcker, Danny Jonigk, Cornelia Kropf-Sanchen, Amanda Tufman, Andreas Draube, Albrecht Stenzinger, Mohamed Zaatar, Michael Thomas

{"title":"[Neoadjuvant therapy for resectable non-small cell lung cancer].","authors":"Katrin Welcker, Danny Jonigk, Cornelia Kropf-Sanchen, Amanda Tufman, Andreas Draube, Albrecht Stenzinger, Mohamed Zaatar, Michael Thomas","doi":"10.1055/a-2465-4830","DOIUrl":"10.1055/a-2465-4830","url":null,"abstract":"Treatment perspectives for non-small cell lung cancer (NSCLC) have been significantly expanded by the integration of immune checkpoint inhibitors into multimodal therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy concepts are also advancing into early, resectable stages of NSCLC. Neoadjuvant and perioperative chemoimmunotherapy opened up a promising new preoperative treatment approach, but also raises some new questions and challenges. With the expanded perioperative treatment options and the perspective on a further improvement in the absence of recurrence after tumor resection, there is push towards comprehensively collecting therapy-relevant findings for imaging, molecular and histopathological diagnostics at an early stage. All patients with lung carcinoma, regardless of the therapy intention, should be presented to an interdisciplinary tumor board with thoracic oncological expertise. This is regularly given in certified lung cancer centers.A standardized procedure contributes to optimized pre-therapeutic diagnostics and facilitates coordination for the best possible multimodal approach in the interdisciplinary tumor board. In the case of centrally located resectable tumors, for example, neoadjuvant treatment increases the chances of a procedure that is as parenchymal sparing as possible. Some questions cannot yet be answered conclusively. Perioperative systemic therapy with molecular-targeted and immune checkpoint inhibitors is the subject of numerous ongoing studies. The considerable dynamics in newly approved therapies and the development of perioperative therapy concepts require continuous adaptation of diagnostic algorithms and standards. Integration into standard pre-surgical routine makes rapid classification of the relevant findings as well as close coordination between the diagnostic and interventional disciplines essential.","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"16-24"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Everything under control?] [一切尽在掌握？ ]

IF 1.2

Pneumologie Pub Date : 2025-01-01 Epub Date: 2024-05-23 DOI: 10.1055/a-2313-4137

Johanna Eggeling, Barbara Kalsdorf, Dagmar Schaub, Stefanie Schierholz, Peter Hammerl, Dennis Nowak, Christoph Lange

引用次数: 0

Sekretolyse – mögliche Vorgehensweisen. 分泌溶解--可能的程序。

IF 1.2

Pneumologie Pub Date : 2025-01-01 Epub Date: 2024-11-18 DOI: 10.1055/a-1935-2240

Thomas Hillmann

引用次数: 0

[Integration of Palliative Medicine in respiratory care]. [姑息医学在呼吸系统护理中的整合]。

IF 1.2

Pneumologie Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI: 10.1055/a-2097-5347

Sandra Delis, Rüdiger Karpf-Wissel

引用次数: 0